Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $39.2778.

A number of equities research analysts have recently commented on GMAB shares. TD Cowen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their price target for the stock from $32.00 to $43.00 in a report on Wednesday. Weiss Ratings lowered shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. New Street Research set a $43.00 target price on shares of Genmab A/S in a research note on Wednesday. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Finally, HC Wainwright increased their price target on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its stake in shares of Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the period. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in shares of Genmab A/S in the first quarter valued at $34,000. Brown Brothers Harriman & Co. grew its holdings in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares in the last quarter. Finally, Founders Capital Management grew its holdings in Genmab A/S by 40.0% during the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Genmab A/S stock opened at $28.85 on Friday. The company has a market cap of $17.99 billion, a P/E ratio of 21.86, a price-to-earnings-growth ratio of 1.80 and a beta of 0.84. Genmab A/S has a one year low of $21.00 and a one year high of $35.43. The business has a fifty day moving average of $26.72 and a two-hundred day moving average of $28.34. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.